CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Bristol Myers Squibb CO (BMY) / mezigdomide
Forward catalyst · BMY

mezigdomide

Sponsor Bristol Myers Squibb CO · listed as BMY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

mezigdomide is a clinical-stage drug asset sponsored by Bristol Myers Squibb CO, listed as BMY. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Jul 18, 2026 (day precision, medium confidence), tied to trial NCT05552976. The asset is in Phase 3 and currently active not recruiting, studied in Relapsed or Refractory Multiple Myeloma. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-07-18
As disclosedJul 18, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05552976
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorBristol-Myers Squibb
Listed asBMY
Condition(s)Relapsed or Refractory Multiple Myeloma

All tracked catalysts for mezigdomide

DateEventConfidenceTrial
2026-07-18READOUTmediumNCT05552976
2027-01-10READOUTmediumNCT05519085
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More BMY catalysts